Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2019-03-28 Investor Presentation
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Investor Presentation 2018
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Biotest Group: FY 2018 at a glance'. It contains financial highlights, income statements, balance sheet data, cash flow analysis, dividend proposals, and strategic outlooks (Guidance 2019). It is clearly an investor-facing presentation summarizing the fiscal year performance, which fits the definition of an Investor Presentation (IP). FY 2018
2019-03-28 English
Investor Presentation 2018
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Biotest Group: FY 2018 at a glance'. It contains financial highlights, income statements, balance sheet data, cash flow analysis, dividend proposals, and strategic outlooks (Guidance 2019). It is clearly an investor-facing presentation summarizing the fiscal year performance, which fits the definition of an Investor Presentation (IP). FY 2018
2019-03-28 German
Magazin zum Geschäftsbericht 2018
Audit Report / Information Classification · 98% confidence The document is titled "WIRKUNG. WERT. SICHERHEIT. | Magazin zum Geschäftsbericht 2018" and contains an 'INHALTSVERZEICHNIS' (Table of Contents) listing sections like 'Interview mit dem Vorstand', 'Höhepunkte des Geschäftsjahres 2018', and detailed discussions about 2018 performance, clinical studies, and outlook for 2019. The content is a comprehensive review of the past fiscal year's activities, financial highlights (mentioning revenue of 400.3 Mio. € and EBIT of 10.6 Mio. € for FY 2018), strategic projects ('Biotest Next Level'), and management commentary. This structure strongly indicates a document summarizing the full annual performance, which aligns with the definition of an Annual Report (10-K), although this specific document appears to be a supplementary magazine or summary accompanying the official filing, given the title 'Magazin zum Geschäftsbericht 2018'. However, since it covers the full year's performance, financial results, and management review, it is functionally equivalent to the content found in a 10-K or a detailed Annual Report (AR). Given the options, and the comprehensive nature covering the entire fiscal year, it is closest to an Annual Report (10-K) or a detailed Audit/Annual Report (AR). Since it is a 'Magazin zum Geschäftsbericht' (Magazine for the Annual Report) and not explicitly labeled as the formal 10-K filing, 'AR' (Audit Report / Information, which often encompasses annual review materials) is a strong candidate, but the depth suggests the core annual review material. Given the context of financial reporting, a document summarizing the entire year's performance, including financial figures and management discussion, is best classified as an Annual Report (10-K) or a detailed Audit Report (AR). Since it is a magazine *about* the annual report, and not the formal filing itself, 'AR' is slightly safer than '10-K' if we strictly interpret the definitions, but the content is clearly the annual review. I will classify it as AR because it is a detailed review of the year's results, which fits the description better than a simple earnings release (ER) or interim report (IR). FY 2018
2019-03-28 German
Magazine for Annual Report 2018
Annual Report Classification · 95% confidence The document is titled 'Magazine for Annual Report 2018' and contains an interview with the Board of Management, a review of the 2018 financial year, highlights of the year, and discussions on company strategy and operations. While it is presented in a magazine format, it serves as the core narrative and management discussion component of the company's annual reporting cycle. Given the comprehensive nature of the content covering the fiscal year 2018, it is classified as an Annual Report. FY 2018
2019-03-28 English
Biotest AG: Biotest receives approval for double concentrated Haemoctin(R) SDH for improved haemophilia A treatment in Europe
Regulatory Filings Classification · 100% confidence The document is a press release dated March 12, 2019, announcing that Biotest AG has received regulatory approval in 13 European countries for a double-concentrated version of its Haemoctin(R) SDH product. It details the product improvement, market launch plans, and provides company background. This type of announcement, focusing on a specific regulatory event (approval) that is not a full financial report (10-K, IR) or a general earnings release (ER), fits best under the general 'Regulatory Filings' category (RNS) as it is a specific corporate news item disseminated via a news service (DGAP). It is not a management change (MANG), director dealing (DIRS), or a formal financial report.
2019-03-12 English
Biotest AG: Dr Michael Ramroth to become new CEO of Biotest AG
Board/Management Information Classification · 100% confidence The document is an 'Ad-hoc RELEASE' dated March 7, 2019, announcing a change in senior management: 'Dr Michael Ramroth to become new CEO of Biotest AG'. This explicitly details a change in the company's senior management/board structure. According to the definitions, this aligns perfectly with the Board/Management Information category (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific personnel announcement.
2019-03-07 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.